

# Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome – patient considerations [Corrigendum]

Kesayan T, Shaw JD, Jones TM, Staffetti JS, Zesiewicz TA. Degenerative Neurological and Neuromuscular Disease 2015;5:63–72.

The authors would like to correct the following errors: on page 64; paragraph 1, “RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 6 mg/24 hours, with recommended titration of 2 mg/24 hours weekly.<sup>5</sup> For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours.”<sup>7</sup> should be “RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 8 mg/24 hours (2–6 mg/24 hours in the US), with recommended titration of 2 mg/24 hours weekly.<sup>5</sup> For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional

2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours (4–8 mg/24 hours in the US).<sup>5</sup>”

On page 64; paragraph 5, “The mean RTG dose was 8 mg/24 hours, while the mean ropinirole dose was 14.1 mg/day.” should have been “The majority of patients (92%) received RTG maintenance dose of 8 mg/24 h, while the median ropinirole dose was 14.1 mg/day.”

On page 64; paragraph 6, “Three hundred and forty-one patients were randomized to receive RTG 8 mg/24 hours, 12 mg/24 hours, or placebo for 28 weeks.” should have been “Three hundred and forty-one patients were randomized to receive RTG up to 8 mg/24 hours, up to 12 mg/24 hours, or placebo for 28 weeks.”

On page 65; Table 1, data in the Doses column and the Notes section have been updated.

**Table 1** Efficacy of RTG in early and advanced PD

	Dose (mg/24 hour)	n	Change from baseline ± SD (P-value)	
			UPDRS II ADL	UPDRS III motor
Early PD				
Güldenpfennig et al <sup>10</sup>	8 mg/24 hour <sup>a</sup>	25	−2.84±3.45 (0.0004)	−4.88±5.56 (0.0002)
	<8 mg/24 hour <sup>a</sup>	4	−2.25±2.36 (0.1622)	−3.00±3.56 (0.1671)
	Plo	0	–	–
Jankovic et al <sup>21</sup>	5.7 mg/24 hour <sup>b</sup>	177	−0.39 ±0.26 (0.002)	−3.58±0.54 (0.001)
	Plo	96	0.92±0.35 (0.002)	0.38±0.73 (0.001)
Parkinson Study Group <sup>22</sup>	2 mg/24 hour <sup>a</sup>	49	−0.04 (0.94)	−0.90 (0.44)
	4 mg/24 hour <sup>a</sup>	47	−0.84 (0.11)	−1.88 (0.11)
	6 mg/24 hour <sup>a</sup>	48	−0.92 (0.08)	−3.91 (0.001)
	8 mg/24 hour <sup>a</sup>	51	−1.56 (0.003)	−3.82 (0.001)
	Plo	47	–	–
Watts et al <sup>23</sup>	5.7 mg <sup>b</sup>	180	−0.30±3.54	−3.50±7.26
	Plo	96	–	–
Giladi et al <sup>2</sup>	8 mg <sup>c</sup>	215	−2.1 <sup>d</sup>	−5.2 <sup>d</sup>
	Plo	118	−0.1	−2.1
Trenkwalder et al <sup>25</sup>	2–16 mg	178	−2.6±3.6	−7.0 (0.002)
	Plo	89	−1.3±3.4	−3.9
Advanced PD				
LeWitt et al <sup>26</sup>	≤8 mg/24 h	113	−3.1 (0.004)	−6.8 (0.0185)
	≤12 mg/24 h	109	−3.2 (0.0023)	−8.7 (0.0006)
	Plo	119	−0.5	−3.4

(Continued)

**Table 1** (Continued)

	Dose (mg/24 hour)	n	Change from baseline $\pm$ SD (P-value)	
			UPDRS II ADL	UPDRS III motor
Poewe et al <sup>27</sup>	4–16 mg/24 hour	201	–4.2 $\pm$ 4.5 (<0.0001)	–8.7 $\pm$ 8.0 (<0.0001)
	Plo	100	–2.0 $\pm$ 4.3 (<0.0001)	–4.3 $\pm$ 9.3 (<0.0001)

**Notes:** <sup>a</sup>RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information<sup>3</sup>), ie, 4.5 mg is equivalent to 2 mg/24 h, 9 mg to 4 mg/24 h, 13.5 mg to 6 mg/24 h, and 18 mg to 8 mg/24 h; <sup>b</sup>The mean (SD) dose was 5.7 (0.84) mg/24 h; 6 mg dose for majority of participants; <sup>c</sup>Ninety-two percent of those in the RTG group were treated with this dose in the maintenance phase and 8% had lower doses; there was no SD reported for UPDRS II or III separately; however, the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase ( $P<0.0001$ ); <sup>d</sup>there was no SD reported for UPDRS II or III separately, however the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase ( $P<0.0001$ ).

**Abbreviations:** RTG, rotigotine; PD, Parkinson's disease; UPDRS II, Unified Parkinson's Disease Rating Scale part II (activities of daily living); UPDRS III, Unified Parkinson's Disease Rating Scale part III (motor examination); Plo, placebo.

**Table 3** Efficacy of RTG in RLS – change from baseline  $\pm$  SD (P-value)

Study, dose (mg/24 hour)	n	IRLS total score $\pm$ SD (P-value)	CGI-I score $\pm$ SD (P-value)	PSQI total score $\pm$ SD (P-value)
Inoue et al <sup>40</sup>				
2 mg	95	–14.3 $\pm$ 8.9 (0.030)	–	–3.1 $\pm$ 3.2 (0.188)
3 mg	94	–14.6 $\pm$ 9.0 (0.016)	–	–3.2 $\pm$ 3.3 (0.112)
Plo	95	–11.6 $\pm$ 8.2	–	–2.5 $\pm$ 2.4
Oertel et al <sup>24</sup>				
2 mg <sup>a</sup>	41	–16.5 $\pm$ 9.3	–2.7 $\pm$ 1.4	–
Plo	20	–9.9 $\pm$ 9.9	–1.7 $\pm$ 1.5	–
Hening et al <sup>10</sup>				
0.5 mg	98	–10.9 $\pm$ 8.9 (0.0682)	4.7 $\pm$ 0.8 (0.0603)	–
1 mg	99	–11.1 $\pm$ 9.3 (0.0535)	4.6 $\pm$ 0.7 (0.0857)	–
2 mg	95	–13.4 $\pm$ 9.2 (0.0002)	4.7 $\pm$ 0.8 (0.0007)	–
3 mg	103	–14.3 $\pm$ 9.4 (<0.0001)	4.7 $\pm$ 0.8 (<0.0001)	–
Plo	99	–9.0 $\pm$ 7.7	4.7 $\pm$ 0.6	–
Trenkwalder et al <sup>8</sup>				
1 mg	148	–14.0 $\pm$ 0.8 (<0.0001)	–2.13 $\pm$ 0.12 (<0.0001)	–
2 mg	96	–16.4 $\pm$ 1.0 (<0.0001)	–2.41 $\pm$ 0.14 (<0.0001)	–
3 mg	92	–16.8 $\pm$ 1.1 (<0.0001)	–2.55 $\pm$ 0.17 (<0.0001)	–
Plo	111	–8.7 $\pm$ 0.9	–1.37 $\pm$ 0.15	–
Oertel et al <sup>9</sup>				
0.5 mg	50	–10.5 $\pm$ 9.2 (0.2338)	–1.6 $\pm$ 1.4	–
1 mg	64	–15.3 $\pm$ 10.0 (0.0004)	–2.2 $\pm$ 1.5 (<0.05)	–
2 mg	49	–15.7 $\pm$ 9.5 (0.0003)	–2.4 $\pm$ 1.3 (<0.05)	–
3 mg	64	–17.3 $\pm$ 10.5 (<0.0001)	–2.7 $\pm$ 1.6 (<0.05)	–
4 mg	53	–14.9 $\pm$ 10.3 (0.0013)	–2.3 $\pm$ 1.5 (<0.05)	–
Plo	53	–9.3 $\pm$ 9.6	–1.5 $\pm$ 1.4	–
Stiasny-Kolster <sup>41</sup>				
0.5 mg/24 hour <sup>b</sup>	19	–10.5 $\pm$ 2.0	–	–
1 mg/24 hour <sup>b</sup>	13	–12.3 $\pm$ 2.3	–	–
2 mg/24 hour <sup>b</sup>	17	–15.7 $\pm$ 1.9	–	–
Plo	14	–8.0 $\pm$ 2.2	–	–

**Notes:** <sup>a</sup>A mean dose of RTG in the treatment group was reported as 2.1 mg/24 hours; <sup>b</sup>RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information<sup>3</sup>), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h.

**Abbreviations:** RTG, rotigotine; RLS, restless legs syndrome; SD, standard deviation; IRLS, International Restless Legs Syndrome Study Group severity rating scale; CGI-I, Clinical Global Impressions item-I; PSQI, Pittsburgh Sleep Quality Index; Plo, placebo.

On page 66; paragraph 2, “In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (<1.5 mg/day), or ropinirole (<6.0 mg/day), and RTG (<8 mg/24 hours) for an 8-week treatment period.”<sup>73</sup> should have been “In an open-label study, advanced-PD patients were treated with levodopa, pramipexole ( $\leq$ 1.5 mg/day), or

ropinirole ( $\leq$ 6.0 mg/day), and RTG ( $\leq$ 8 mg/24 hours) for an 8-week treatment period.”<sup>73</sup>

On page 68; Table 3, data in the Study, doses column for the Stiasny-Kolster study and the Notes section have been updated.

On page 69; Table 4, the data for the Stiasny–Kolster study and the Notes section have been updated.

**Table 4** Side effects present in participants (%) during randomized, double-blinded, placebo-controlled trials

Side effect	Dose (mg/24 hour)	Inoue et al <sup>40</sup>		Hening et al <sup>10</sup>		Trenkwalder et al <sup>8</sup>		Oertel et al <sup>9</sup>		Oertel et al <sup>24,a</sup>		Stiasny–Kolster <sup>41,b</sup>	
		RTG	Plo	RTG	Plo	RTG	Plo	RTG	Plo	RTG	Plo	RTG	Plo
Application site reaction	0.5 mg	–	7.4	22.2	5.0	–	–	9.8	1.8	–	4.8	17.6	28.6
	1 mg	–	–	17	–	35.0	2.0	15.6	–	–	–	38.5	–
	2 mg	42.1	–	34.3	–	41.0	–	16.3	–	17.4	–	26.3	–
	3 mg	50.0	–	34	–	52.0	–	20	–	–	–	–	–
	4 mg	–	–	–	–	–	–	25	–	–	–	–	–
Headache	0.5 mg	–	0	14.1	8.0	–	–	11.8	7.3	–	14.3	11.8	7.1
	1 mg	–	–	12	–	10.0	7.0	7.8	–	–	–	38.5	–
	2 mg	5.3	–	10.1	–	13.0	–	2	–	17.4	–	21.1	–
	3 mg	2.1	–	10.4	–	16.0	–	4.6	–	–	–	–	–
	4 mg	–	–	–	–	–	–	12.5	–	–	–	–	–
Nausea	0.5 mg	–	9.5	13.1	10.0	–	–	5.9	9.1	–	4.8	0.0	14.3
	1 mg	–	–	20	–	9.0	–	9.4	–	–	–	7.7	–
	2 mg	33.7	–	18.2	–	21.0	–	6.1	–	21.7	–	5.3	–
	3 mg	43.6	–	20.8	–	18.0	–	24.6	–	–	–	–	–
	4 mg	–	–	–	–	–	–	23.2	–	–	–	–	–
Fatigue	0.5 mg	–	–	10.1	4.0	–	–	3.9	9.1	–	9.5	0.0	0.0
	1 mg	–	–	3	–	7.0	9.0	4.7	–	–	–	0.0	–
	2 mg	–	–	7.1	–	15.0	–	6.1	–	8.7	–	10.5	–
	3 mg	–	–	6.6	–	11.0	–	10.8	–	–	–	–	–
	4 mg	–	–	–	–	–	–	7.1	–	–	–	–	–
Pruritus	0.5 mg	–	–	9.1	2.0	–	–	5.9	1.8	–	–	5.9	7.1
	1 mg	–	–	2	–	–	–	3.1	–	–	–	15.4	–
	2 mg	–	–	3	–	–	–	0	–	–	–	0.0	–
	3 mg	–	–	7.5	–	–	–	10.8	–	–	–	–	–
	4 mg	–	–	–	–	–	–	3.6	–	–	–	–	–
Hyperhidrosis	0.5 mg	–	–	–	–	–	–	–	–	–	–	–	0.0
	1 mg	–	–	–	–	5.0	3.0	–	–	–	–	0.0	–
	2 mg	–	–	–	–	6.0	–	–	–	–	–	0.0	–
	3 mg	–	–	–	–	4.0	–	–	–	–	–	10.5	–
	4 mg	–	–	–	–	–	–	–	–	–	–	–	–
Somnolence	0.5 mg	–	2.1	8.1	6.0	–	–	–	–	–	9.5	–	–
	1 mg	–	–	10.0	–	–	–	–	–	–	–	–	–
	2 mg	10.5	–	13.1	–	–	–	–	–	10.9	–	–	–
	3 mg	–	–	15.1	–	–	–	–	–	–	–	–	–
	4 mg	–	–	–	–	–	–	–	–	–	–	–	–

**Notes:** <sup>a</sup>The study did not report the association of adverse events (AE) in relation to the dose of RTG. A mean dose of RTG in the treatment group was reported as 2.1 mg/24 hours; <sup>b</sup>RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information<sup>5</sup>), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h.

**Abbreviations:** RTG, rotigotine; Plo, placebo.

## Degenerative Neurological and Neuromuscular Disease

Dovepress

### Publish your work in this journal

Degenerative Neurological and Neuromuscular Disease is an international, peer-reviewed, open access journal focusing on research into degenerative neurological and neuromuscular disease, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced

survival and quality of life for the patient. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/degenerative-neurological-and-neuromuscular-disease-journal>